ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia

The deregulated kinase activity of p210-BCR/ABL oncoproteins, hallmark of chronic myelogenous leukaemia (CML), induces and sustains the leukaemic phenotype, and contributes to disease progression. Imatinib mesylate, a BCR/ABL kinase inhibitor, is effective in most of chronic phase CML patients. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrotti, D, Neviani, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360538/
https://www.ncbi.nlm.nih.gov/pubmed/16953242
http://dx.doi.org/10.1038/sj.bjc.6603317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360538/
https://www.ncbi.nlm.nih.gov/pubmed/16953242
http://dx.doi.org/10.1038/sj.bjc.6603317

Ejemplares similares